Cyclooxygenase-2: Its rich diversity of roles and possible application of its selective inhibitors

Inflammation Research

Volumn 49, Issue 8, 2000, Pages 367-392

  Katori, M ^a   Majima, M ^b  

^a Higashi 1 14 3   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Colon cancer; COX 2 inhibitors; Fever; Inflammation; Reproduction

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PROSTANOID; ROFECOXIB;

ALZHEIMER DISEASE; ANGIOGENESIS; ARTHRITIS; BONE ATROPHY; COLON CANCER; DRUG INDICATION; DRUG SAFETY; GENE EXPRESSION; HUMAN; HYPERALGESIA; INFLAMMATION; INFLAMMATORY DISEASE; KNOCKOUT MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; STOMACH ULCER;

ANIMALS; CENTRAL NERVOUS SYSTEM; COLONIC NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEVER; HUMANS; INFLAMMATION; ISOENZYMES; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REPRODUCTION;

EID: 0033833320     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050605     Document Type: Review

References (326)

1. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation
2. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
3. TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cycloxygenase homologue
4. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
5. Human cyclooxygenase-2 cDNA
6. Prostanoid receptors: Structure, function, and distribution
7. International Union of Pharmacology Classification of Prostanoid Receptors: Properties, distribution, and structure of the receptors and their subtypes
8. Differential effects of indomethacin and dexamethasone on cytokine production in carrageenin-induced rat pleurisy
9. Autonomic neurotransmission
10. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
11. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice
12. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme
13. Dexamethasone inhibits mitogen induction of the T1S10 prostaglandin synthase/cyclooxygenase gene
14. Relation between inhibition of cyclooxygenase-2 and anti-inflammatory effects of dexamethasone
15. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation
16. Detection of inducible prostaglandin H synthase-2 in cells in the exudate of rat carrageenin-induced pleurisy
17. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
18. 2 production by IFN-gamma in human macrophages
19. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide
20. Transient expression of prostaglandin endoperoxide synthase-2 during mouse macrophage activation
21. Cyclooxygenase-2 expression by endothelin-1-stimulated mouse resident peritoneal macrophages in vitro
22. 2 in a murine model of inflammation: Possible role of cyclooxygenase-2
23. Inflammatory agonists induce cyclooxygenase type 2 expression by human neutrophils
24. Suppression of prostaglandin H synthase-2 induction in human monocytes by in vitro administration of interleukin-4
25. Differential sensitivities of human monocytes and alveolar macrophages to the inhibition of prostaglandin endoperoxide synthase-2 by interleukin-4
26. 2, and matrix metalloproteinases
27. Differential regulation of cyclooxygenase 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts
28. Interferon gamma induces prostaglandin G/H synthase-2 through an autocrine loop via the epidermal growth factor in human bronchial epithelial cells
29. Constitutive expression of prostaglandin endoperoxideG/H synthetase (PGHS)-2 but not PGHS-1 in human tracheal epithelial cells in vitro
30. Staphylococcal exoproducts down-regulate cyclooxygenase 1 and 2 in peritoneal macrophages
31. Cultured lung fibroblasts with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to excess cyclooxygenase-2
32. 2 in lipopolysaccharide-stimulated peritoneal macrophages
33. 2 generation in immature mouse mast cells
34. 4 synthase pathway in mouse mast cell
35. 2 in mouse bone marrow-derived mast cells
36. 2 generation via prostaglandin endoperoxide synthase-2
37. 2 and 5-lipoxygenase
38. 2 and prostaglandin endoperoxide synthase-2 and their roles in separate pathways of eicosanoid synthesis in mouse bone marrow-derived mast cells
39. 2s and cyclooxygenases in immediate and delayed prostanoid biosynthesis pathways
40. Different substrate utilization between prostaglandin endoperoxide H synthase-1 and -2 in NIH 3T3 fibroblasts
41. Expression of the two isoforms of prostaglandin endoperoxide synthase (PGHS-1 and PGHS-2) during adipose cell differentiation
42. Pharmacological analysis of cyclooxygenase-1 in inflammation
43. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity
44. Selective COX-2 inhibitors: Is the water becoming muddy?
45. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions
46. 2 formation in rat carrageenin-induced pleurisy
47. Release of endogenous prostaglandins by mild hyperosmotic saline inhibits tetragastrin-stimulated gastric acid secretion in rats
48. 2 generation after administration of mild hypertonic saline solution into the gastric lumen
49. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
50. Changes of prostaglandin and thromboxane levels in pleural fluid of rat carrageenin-induced pleurisy
51. Changes in the levels of prostaglandins and thromboxanes and their roles in the accumulation of exudate in rat carrageenin-induced pleurisy - A profile analysis using gas chromatography mass spectrometry
52. Activation of plasma kallikrein-kinin system and its significant role in pleural fluid accumulation of rat carrageenin-induced pleurisy
53. Induction of prostaglandin H synthase-2 in rat carrageenin-induced pleurisy and effect of a selective COX-2 inhibitor
54. 2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo
55. Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy
56. Differential effects of inhibitors of cyclooxygenases (cyclooxygenase-1 and cyclooxygenase 2) in acute inflammation
57. Selective inhibition of inducible cyclooxygenease 2 in vivo is antiinflammatory and nonulcerogenic
58. Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo
59. Cyclooxygenase isoenzyme localization and mRNA expression in rat lung
60. Prostaglandin H synthase 1 and 2 immunoreactivities in the bronchial mucosa of asthmatics
61. Mediation of inflammation by encephalitogenic cells: Interferon gamma induction of nitric oxide synthase and cyclooxygenase-2
62. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
63. Evaluation for antiinflammatory activity
64. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
65. Involvement of histamine in vascular permeability increase of the rat pleurisy induced by phorbol myristate acetate
66. 2 in rat pleurisy induced by phorbol miristate acetate
67. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
68. Possible participation of cyclooxygenase-2 in the recurrence of allergic inflammation in rats
69. Effects of JTE-522, as selective inhibitor of cyclooxygenase-2, on the recurrence of allergic inflammation in rats
70. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2(COX-2) in culture fibroblasts
71. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation
72. Nitric oxide synthase and cyclo-oxygenase pathways in the inflammatory response induced by zymosan in the rat air pouch
73. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammatory and expression of COX-2 and interleukin 6 in rat adjuvant arthritis
74. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis
75. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis
76. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol miristate ester, and corticosteroids
77. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes
78. Interleukin-4 inhibits prostaglandin E2 production by freshly prepared adherent rheumatoid synovial cell via inhibition of biosynthesis and gene expression of cyclo-oxygenase II but not of cyclo-oxygenase I
79. Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1
80. 2
81. 2 production by rat peritoneal macrophages
82. 2 production depenent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages
83. Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis
84. Prostaglandins as transducers of proliferation signals in microvascular endothelial cells and the pharmacological control of angiogenesis
85. Significant roles of inducible cyclooxygenase (COX-2) in angiogenesis in rat sponge implants
86. Cyclooxygenase-2 enhances angiogenesis through induction of vascular endothelial growth factor in rat sponge implants
87. The role of prostaglandins in regulation of bone metabolism
88. Expression of prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide synthase-2 in human osteoblasts
89. Regulation of prostaglandin G/H synthase-2 expression by interleukin-1 in human osteoblast-like cells
90. Differential regulation of inducible and constitutive prostaglandin endoperoxide synthase in osteoblastic MC3T3-E1 cells
91. Involvement of cyclooxygenase-2 in bone loss induced by interleukin-1b
92. Transcriptional induction of prostaglandin G/H synthase-2 by basic fibroblast growth factor
93. Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation
94. Pulsating fluid flow stimulates prostaglandin release and inducible prostaglandin G/H synthase mRNA expression in primary mouse bone cells
95. Autoregulation of inducible prostaglandin G/H synthase in osteoblastic cells by prostaglandins
96. Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells
97. 2) autoamplifies its production through EP 1 subtype of PGE receptor in mouse osteoblastic MC3T3-E1
98. 2 receptor of EPs subtype
99. Expression and regulation of prostaglandin F receptor mRNA in rodent osteoblastic cells
100. 2 induction in neonatal mouse parietal bone cultures
101. IL-13 and IL-14 inhibit bone absorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts
102. Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae
103. Characterization of prostaglandin G/H synthase-1 and -2 in rat, dog, monkey, and human gastrointestinal tracts
104. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats
105. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues
106. Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach
107. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
108. Role of cyclooxygenase-2 in the healing of gastric ulcer in rats
109. Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach
110. Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcer in rats
111. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: Interaction with indomethacin
112. Diclofenac delays healing of gastroduodenal mucosal lesions - Double-blind, placebo-controlled endoscopic study in healthy volunteers
113. Exacerbation of inflmmation-associated colonic injury in rat through inhibition of cyclooxygenase-2
114. Bacterial lipopolysaccharides protects gastric mucosa against acute injury in rats by activation of genes for cyclooxygenases and endogenous prostaglandins
115. Quantitative analysis of cyclooxygenase-2 gene expression on acute gastric injury induced by ischemiareperfusion in rats
116. Nonsteroidal antiinflammatory drugs and human cancer
117. Aspirin use and reduced risk of fatal colon cancer
118. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer J
119. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group
120. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
121. Aspirin use, cancer, and polyps of the large bowel
122. Aspirin use and risk of fatal cancer
123. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
124. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
125. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncation Apc gene
126. Suppression of intestinal polyposis in ApcD716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
127. Elevated cyclooxygenase-2 levels in Min mouse adenomas
128. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)
129. Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
130. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2
131. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cell lines
132. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
133. Inhibition of human colon cancer cell growth by seletive inhibition of cyclooxygenase-2
134. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats
135. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
136. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice
137. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice
138. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
139. Prospective study of regular aspirin use and the risk of breast cancer
140. Non-steroidal antiinflammatory drugs and breast cancer
141. Cyclooxygenase-2 gene expression in human breast cancer
142. 2 production and metabolism in human breast cancer cells and cell fibroblasts. Regulation by inflammatory mediators
143. Cyclooxygenase-2 gene expression is upregulated in transformed mammary epithelial cells
144. Compartmentalization of prostaglandin and prostacyclin within the kidney: Implications for renal function
145. Renal effects of nonsteroidal anti-inflammatory drugs
146. The effects of prostaglandin synthetase inhibitors on renal function: Studies in normal rats during sodium or water diuresis and in rats with chronic renal insufficiency
147. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
148. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells
149. Differential regulation of renal cyclooxygenase mRNA by dietary salt intake
150. Selective increase of cyclooxygenase-2 expression in a model of renal ablation
151. Regulation of cyclooxygenase expression in the kidney by dietary intake
152. Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal antiinflammatory drug-related nephrotoxicity
153. Effect of papillotoxic agents on expression of cyclooxygenase isoforms in the rat kidney
154. Role of chloride in the variable response of the kidney to cyclooxygenase inhibition
155. Contribution of prostaglandins to the systemic and renal vascular response to frusemide in normal man
156. Effect of selective inhibition of the inducible cyclooxygenase on renin release in healthy volunteers
157. Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells
158. Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet
159. Prostaglandin synthetase activity in kidney medulla during developmental hypertension in the rat
160. Prostaglandins are involved in the stimulation of renin gene expression in 2 kidney-1 clip rats
161. Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension
162. Cyclooxygenase-2 inhibition decreases renin contenet and lowers blood pressure in a model of renovascular hypertension
163. Antihypertensive effect of a cyclooxygenase-2 inhibitor on renovascular hypertension
164. Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs
165. Cyclooxygenase-2 in rat nephron development
166. Constitutive expression of cyclooxygenase-2 in rat vas deferens
167. Indomethacin and aspirin abolish prostaglandin release from the spleen
168. Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs
169. Prostaglandins, aspirin-like drugs and analgesia
170. Effects of prostaglandins and other putative chemical intermediaries on the activity of canine testicular polymodal receptors studied in vitro
171. EP receptor subtypes implicated in the PGE2-induced sensitization of polymodal receptors in response to bradykinin and heat
172. Differences in the response of the polymodal receptor to heat stimulation and to bradykinin
173. 2
174. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats
175. L-745, 337: A selective inhibitor of cyclooygenase-2 elicits antinociception, but not gastric ulceraion in rats
176. Nimesulide in the treatment of osteoarthritis. Double-blind studies in comparison with piroxicam, ketoprofen and placebo
177. Nimesulide in the short-term treatment of inflammatory process of dental tissues: A double-blind controlled trial against oxyphenbutazone
178. Alterations in intrauterine pressure, menstrual fluid prostaglandin F levels, and pain in dysmenorrheic women with nimesulide
179. Potentiation of bradykinin-induced nociceptive response by arachidonate metabolites in dogs
180. Mechanism of bradykinin-induced nociceptive response
181. The significant reduction of high-molecular-weight kininogen in synovial fluid of patients with active rheumatoid arthritis
182. Cyclooxygenases and the central nervous system
183. Cyclooxygenase systems in the mammalian brain
184. 2 as a major prostaglandin in homogenates of rat brain
185. 2 in rat brain, spinal cord and pituitary: Basal level and regional distribution
186. 2 and F(2α) in the brain of spontaneously convulsing gerbils
187. Cloning and expression of a cDNA for rat prostaglandin F(2alpha) receptor
188. Neurobiological basis of fever
189. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3
190. Comparison of the antipyretic actions of indomethacin and L-745,337, a selective cyclooxygenase-2 inhibitor, in endotoxin-treated prepubertal pigs
191. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2
192. Characterization of inducible cyclooxygenase in the rat brain
193. 2-binding sites in the anterior wall of the 3rd ventricle - A possible site of its hyperthermic action
194. Inhibition of nitric oxide synthase or cyclo-oxygenase pathway in organum vasculosum laninae terminalis attenuates interleukin-1beta fever in rabbits
195. Intravenous lipopolysaccharide induced cyclooxygenase 2-like immunoreactivity in rat brain perivascular microglia and meningeal macrophages
196. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide
197. Induction by lipopolysaccharides of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response
198. Possible role of cyclooxygenase-2 in the brain vasculature in febrile response
199. Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1 beta: A possible site of prostaglandin synthase responsible for fever
200. Induction of cyclooxygenase-2 in the brain by cytokines
201. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain
202. Brain endothelial cells express cyclooxygenase-2 during lipopolysaccharide-induced fever: Light and electron microscopic immunocytochemical studies
203. Cyclooxygenase-2 is induced in brain blood vessels during fever evoked by peripheral or central administration of tumor necrosis factor
204. Lipopolysaccharide injection into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells
205. 2 sensitive, sleep promoting zone defined in the ventral surface of the rostral basal forebrain
206. Immunochemical localization of prostaglandin firming cyclooxygenase in the cerebellar cortex
207. Transforming growth factor beta 1 regulates the expression of cyclooxygenase in cultured cortical astrocytes and neurons
208. Interleukin-1beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures
209. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain
210. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids
211. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex
212. Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn
213. Prostaglandin-H synthase-1 (PGHS-1) gene is expressed in specific neurons of the brain of the late gestation ovine fetus
214. Expression of prostaglandin endoperoxide synthase in rat brain
215. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: Implications for Alzheimer's disease
216. Induction of PGH synthase and c-fos mRNA during early reperfusion of ischemic rat brain
217. Cyclooxygenase-2 is induced globally in infarcted human brain
218. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia
219. Expression and vascular effects of cyclooxygenase-2 in brain
220. Section V. Drug Therapy of Inflammation, Chapter 29. Analgesic-antipyretics and anti-inflammatory agents: Drugs employed in the treatment of gout
221. Clinical trial of indomethacin in Alzheimer's disease
222. 2 blocking drugs
223. Risk of Alzheimer's disease and duration of NSAID use
224. NSAIDs and cognition in Alzheimer's disease
225. Inhibition of prostaglandin biosynthesis
226. Decreased prostaglandin synthesis in postmortem cerebral cortex from patients with Alzheimer's disease
227. Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease
228. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease
229. Strong nuclear factor-kappa B-DNA binding parallels cyclooxygenase-2 gene trascription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex
230. Spontaneous and evoked release of prostaglandins from frog spinal cord
231. Increased levels of cyclooxygenase -2 mRNA in the rat spinal cord after peripheral inflammation: An in situ hybrization study
232. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
233. Cyclooxygenase-2 in the spinal cord: Localization and regulation after a peripheral inflammatory stimulus
234. 2 receptor EP3 in the rat lumbar spinal cord
235. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat
236. Hyperalgesia mediated by spinal glutamate or SP receptor blocked by spinal cyclooxygenase inhibition
237. Induction of cyclooxygenase type-2 (COX-2) in rat endometrium at the peak of serum estradiol during the estrus cycle
238. Chemokine and cyclooxygenase-2 expression in human endometrium coincides with leukocyte accumulation
239. Immunohistochemical assessment of prostaglandin H-synthase in bovine endometrial biopsy samples collected throughout the oestrus cycle
240. Regulation of prostaglandin endoperoxide H synthase 1 and 2 by estradiol and progesterone in non-pregnant ovine myometrium and endometrium in vivo
241. Expression of cyclooxygenase-1 and -2 in ovine endometrium
242. Progesterone induces expression of endometrial messenger RNA encoding for cyclooxygenase (sheep)
243. Regulation of gene expression and cellular localization of prostaglandin synthase by oestrogen and progesterone in the ovine uterus
244. Interleukin-1 beta induces cyclooxygenase-2 gene expression in cultured endometrial stroma cells
245. Interleukin-1 receptor antagonist blocks interleukin-1-induced expression of cyclooxygenase-2 in endometrium
246. Regulation of cyclooxygenase gene expression in rat endometrial stromal cells: The role of epidermal growth factor
247. Immunohistochemical localization of prostaglandin synthase in the female reproductive tract and endometriosis
248. Endometrial prostaglandins and menorrhagia: Influence of a prostaglandin synthetase inhibitor in vivo
249. Cellular mechanisms involved during oxytocin-induced prostaglandin F(2alpha) production in endometrial epithelial cells in vitro: Role of cyclooxygenase-2
250. Dissociation of ovulatory and steroidogenic actions of luteinizing hormone in rabbits with indomethacin, an inhibitor of prostaglandin biosynthesis
251. Inhibition of ovulation in rabbits by intrafollicular injection of indomethacin and prostaglandin F antiserum
252. Blockade of spontaneous and LH-induced ovulation in rats by indomethacin, an inhibitor of prostaglandin biosynthesis
253. The role of protein synthesis in the stimulation by LH of prostaglandin accumulation in rat preovulatory follicles in vitro
254. Prostaglandin endoperoxide synthase in rat ovarian follicles: Content, cellular distribution, and evidence for hormonal induction preceding ovulation
255. Purification and characterization of a novel, distinct isolation of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles
256. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthase in rat preovulatory follicles
257. Developmental expression of the cyclo-oxygenase-1 and cyclooxygeenase-2 genes in the peri-implant mouse uterus and their differential regulation by the blastocyst and ovarian steroids
258. Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua
259. 2 production from early first trimester human decidual cells is inhibited by dexamethasone and progesterone
260. Immunohistological localization of prostaglandin H synthase in the sheep placenta from early pregnancy to term
261. The relative abundance of type 1 to type 2 cyclo-oxygenase mRNA in human amnion at term
262. Expression of cyclooxygenase types 1 and 2 in human fetal membranes at term
263. Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons
264. Regulation of bovine cervical secretion of prostaglandins and synthesis of cyclooxygenase by oxytocin
265. Interleukin-1β regulates the inducible cyclooxygenase in amnion-derived WISH cells
266. Interleukin-1 beta induces cyclooxygenase-2 in cultured human decidual cells
267. Tumor necrosis factor-alpha promotes sustained cyclooxygenase-2 expression: Attenuation by dexamethasone and NSAIDs
268. Lipopolysaccharide enhances the transcription of prostaglandin H synthase-2 gene in primary human trophoblasts
269. Towards a better aspirin
270. New insights into the mode of action of anti-inflammatory drugs
271. The discovery and function of COX-2
272. Mechanism of action of nonsteroidal anti-inflammatory drugs
273. Anti-inflammatory drugs and their mechanism of action
274. Cyclooxygenases 1 and 2
275. Nonsteroidal drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
276. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
277. Activity of nimesulide on constitutive and inducible cyclooxygenases
278. Effects of nimesulide, a preferential cyclooxygenase-2 inhibitor, on carrageenin-induced pleurisy and stress-induced gastric lesions in rats
279. Selective cyclooxygenase-2 inhibition by nimesulide in man
280. Long term tolerability profile of nimesulide in the treatment of osteoarthritis
281. Treatment of tendinitis and bursitis: A comparison of nimesulide and naproxen sodium in a double-blind parallel trial
282. Nimesulide in the treatment of fever. A double-blind, crossover clinical trial
283. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs
284. Risk of hopitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
285. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1
286. Etodolac therapy for osteoarthritis: A double-blind, placebo-controlled trial
287. Worldwide experience with etodolac (Lodine) 300 mg b.i.d. in the treatment of osteoarthritis
288. Etodolac (Lodine) in the treatment of osteoarthritis: Recent studies
289. Meta-analysis of three double-blind compartative trials with sustained-release etocolac in the treatment of osteoarthritis of the knee
290. Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee
291. Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis
292. Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis
293. Comparison of etodolac, aspirin and placebo for pain after oral surgery
294. Evaluation of pharmacological profile of meloxicam as an antiinflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1
295. Clinical pharmacokinetics of meloxicam
296. A review of the clinical pharmacokinetics of meloxicam
297. Effects of meloxicam and idnomethacin on cyclooxygenase pathways in healthy volunteers
298. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee
299. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip
300. Meloxicam in osteoarthritis: A 6 month, double-blind comparison with diclofenac sodium
301. Efficacy and safety of meloxicam in patients with rheumatoid arthritis
302. A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis
303. A six-month double-blind trial to compare the efficacy and safety of meloxicam 75 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis
304. Review of clinical trials and benefit/risk ratio of meloxicam
305. Safety of meloxicam: A global analysis of clinical trials
306. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers
307. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients.International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment
308. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis
309. Outcome of specific COX-2 inhibition in rheumatoid arthritis
310. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
311. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
312. Pain management in osteoarthritis: The role of COX-2 inhibitors
313. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach
314. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
315. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
316. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
317. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
318. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis
319. Effect of specific COX-2 inhibition in osteoarthritis of tehknee: A 6 week double blind, placebo controlled pilot study of rofecoxib
320. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinicl efficacy comprable with that of diclofenac sodium
321. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
322. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans
323. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial
324. Characterization of rofecoxib as acyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
325. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and acitve-comparator-controlled trial